EBMT 2022 | State of the art in CML
Guillermo Ortí
• 21 Mar 2022
Guillermo Ortí, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, summarizes current treatment strategies for patients with chronic myeloid leukemia (CML). The frontline management of CML consists of tyrosine kinase inhibitors (TKIs), and patients who relapse usually undergo allogeneic hematopoietic stem cell transplantation (alloHSCT). Patients with CML who progress to accelerated phase (AP) receive alloHSCT while patients who progress to blast phase (AP) are treated with TKIs or alloHSCT if they do not respond to TKIs. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
